Envestnet Portfolio Solutions Inc. Sells 6,962 Shares of Johnson & Johnson $JNJ

Key Points

• Envestnet Portfolio Solutions cut its Johnson & Johnson stake by 8.9% in the second quarter, selling 6,962 shares and retaining 71,666 shares valued at approximately $18.2 million. Institutional investors collectively own 69.55% of J&J.
• Johnson & Johnson reported quarterly EPS of $2.90, beating estimates of $2.84, while revenue rose 6.6% year over year to $25.31 billion. The company also maintains a $1.34 quarterly dividend, equivalent to a 2.0% annual yield.
• Analysts hold a consensus “Moderate Buy” rating with an average price target of $274.13, while insiders have sold 87,569 shares worth about $23.1 million over the past 90 days.

Envestnet Portfolio Solutions Inc. lessened its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 8.9% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 71,666 shares of the company's stock after selling 6,962 shares during the period. Envestnet Portfolio Solutions Inc.'s holdings in Johnson & Johnson were worth $18,191,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Security National Bank of Sioux City Iowa IA lifted its position in shares of Johnson & Johnson by 27.2% in the second quarter. Security National Bank of Sioux City Iowa IA now owns 18,143 shares of the company's stock worth $4,608,000 after buying an additional 3,878 shares in the last quarter. Reynders McVeigh Capital Management LLC increased its position in Johnson & Johnson by 0.7% in the second quarter. Reynders McVeigh Capital Management LLC now owns 76,513 shares of the company's stock worth $19,432,000 after purchasing an additional 499 shares during the last quarter. Bullseye Investment Management LLC purchased a new stake in Johnson & Johnson during the second quarter valued at $63,000. Talon Private Wealth LLC lifted its position in Johnson & Johnson by 89.5% during the second quarter. Talon Private Wealth LLC now owns 10,588 shares of the company's stock valued at $2,689,000 after purchasing an additional 5,002 shares during the last quarter. Finally, U S Wealth Group LLC. grew its stake in shares of Johnson & Johnson by 15.1% in the 2nd quarter. U S Wealth Group LLC. now owns 17,259 shares of the company's stock worth $4,383,000 after buying an additional 2,266 shares in the last quarter. Institutional investors own 69.55% of the company's stock.

Johnson & Johnson Stock Down 0.1%

Shares of NYSE:JNJ opened at $269.01 on Thursday. The company has a quick ratio of 0.81, a current ratio of 1.09 and a debt-to-equity ratio of 0.44. The business's 50 day moving average is $264.73 and its 200 day moving average is $247.24. The stock has a market cap of $648.28 billion, a P/E ratio of 31.17, a price-to-earnings-growth ratio of 2.57 and a beta of 0.24. Johnson & Johnson has a 52-week low of $175.74 and a 52-week high of $281.07.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Wednesday, July 15th. The company reported $2.90 EPS for the quarter, beating the consensus estimate of $2.84 by $0.06. Johnson & Johnson had a return on equity of 32.42% and a net margin of 21.48%.The firm had revenue of $25.31 billion for the quarter, compared to analyst estimates of $25.06 billion. During the same quarter last year, the firm posted $2.77 earnings per share. The business's revenue for the quarter was up 6.6% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. Sell-side analysts predict that Johnson & Johnson will post 11.61 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th were issued a $1.34 dividend. The ex-dividend date was Tuesday, August 25th. This represents a $5.36 dividend on an annualized basis and a yield of 2.0%. Johnson & Johnson's payout ratio is currently 62.11%.

Analysts Set New Price Targets

Several analysts have recently issued reports on JNJ shares. Freedom Capital upgraded shares of Johnson & Johnson from a "hold" rating to a "strong-buy" rating in a research report on Thursday, July 16th. Stifel Nicolaus set a $260.00 price objective on Johnson & Johnson in a research report on Wednesday, July 15th. Citigroup lifted their target price on Johnson & Johnson from $285.00 to $298.00 and gave the stock a "buy" rating in a report on Wednesday, July 8th. UBS Group restated a "buy" rating on shares of Johnson & Johnson in a report on Tuesday. Finally, Royal Bank Of Canada lifted their price objective on shares of Johnson & Johnson from $265.00 to $287.00 and gave the stock an "outperform" rating in a research note on Monday, July 13th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $274.13.

More Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: New Phase 3 modeling for the TECVAYLI plus DARZALEX FASPRO combination estimated that approximately 87% of early-line relapsed/refractory multiple myeloma patients could eventually face mortality risk comparable to the general population. The analysis also projected nearly four-times longer median overall survival versus standard treatment, supporting the long-term growth potential of J&J’s oncology franchise. TECVAYLI and DARZALEX FASPRO analysis
• Positive Sentiment: CAPLYTA delivered statistically significant and rapid symptom improvement in a Phase 3 study of bipolar I mania. If approved for mania in addition to bipolar depression and schizophrenia, the Intra-Cellular Therapies acquisition could support broader revenue growth for J&J’s neuroscience portfolio. CAPLYTA bipolar mania study
• Positive Sentiment: FDA approval of ICOTYDE for moderate-to-severe plaque psoriasis, alongside an ongoing Phase 3 psoriatic arthritis program, expands J&J’s immunology pipeline and provides a potential successor to declining STELARA sales. ICOTYDE immunology push
• Neutral Sentiment: Reports that J&J may divest its DePuy Synthes orthopedics unit suggest a more focused, potentially faster-growing portfolio, but the near-term effect would depend on valuation, proceeds and the assets ultimately retained. DePuy Synthes divestiture
• Negative Sentiment: At roughly 31 times earnings, JNJ’s valuation leaves less room for disappointment. Analysts note that the stock has substantially outperformed peers even though revenue growth has been slower, making investors more sensitive to STELARA erosion, execution risks and any slowdown in newer products. JNJ valuation and peer performance

Insider Activity

In related news, EVP Timothy Schmid sold 33,597 shares of the stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the completion of the sale, the executive vice president owned 25,447 shares of the company's stock, valued at $6,991,308.78. This represents a 56.90% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Elizabeth Forminard sold 15,918 shares of the firm's stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $257.00, for a total transaction of $4,090,926.00. Following the completion of the sale, the executive vice president owned 16,994 shares of the company's stock, valued at approximately $4,367,458. This trade represents a 48.37% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 87,569 shares of company stock valued at $23,064,544. Corporate insiders own 0.16% of the company's stock.

Johnson & Johnson Profile

Johnson & Johnson NYSE: JNJ is a global healthcare company that develops, manufactures and markets pharmaceutical and medical device products. Founded in 1886 and headquartered in New Brunswick, New Jersey, the company serves patients, healthcare professionals and institutions in markets around the world.

Johnson & Johnson operates through two primary business segments: Innovative Medicine and MedTech. Innovative Medicine focuses on prescription treatments in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.